Pharma Focus Asia

BIO INX and Rousselot Forge Partnership to Improve 3D Bioprinting Materials

Friday, March 15, 2024

BIO INX, a notable player in the field of 3D bioprinting material development, has announced a significant advancement through its partnership with Rousselot, a global leader in gelatin and collagen-based solutions. This collaboration signifies a pivotal step forward in bringing 3D bioprinting technologies closer to clinical applications.

As part of this collaboration, BIO INX will distribute Rousselot's well-regarded research and technical grade X-Pure® gelatin biomaterials, known for their exceptional quality and reliability. These advanced materials will be seamlessly integrated into BIO INX's offerings, improving accessibility for researchers and academics worldwide through BIO INX's webshop.

A notable outcome of this collaboration is the development of the X-Pure version of BIO INX's renowned extrusion bioink, GEL-MA INX©. This groundbreaking bioink, developed in partnership with Rousselot, represents a significant step towards a GMP-like gelatin-based bioink, simplifying the printing of constructs with living cells. This development aligns with BIO INX's mission to streamline bioprinting, bringing the technology closer to clinical use by enhancing reproducibility and adhering to elevated quality standards.

The collaboration builds upon the longstanding relationship between BIO INX and Rousselot, with BIO INX originating as a spin-off from Ghent University's Polymer Chemistry and Biomaterials Group, where the original Gelatin Methacryloyl (GEL-MA) was developed and patented 25 years ago using Rousselot gelatin. The research group, now co-led by Professor Sandra Van Vlierberghe, one of BIO INX's cofounders, continues to drive innovation in the field.

Prof. Sandra Van Vlierberghe expressed, "The collaboration with Rousselot adds a new dimension to the popularity of GEL-MA, enhancing its standardization and quality. This advancement bridges the gap between academic research and real-life applications."

BIO INX, emphasized, "This collaboration represents years of shared vision and innovation between BIO INX and Rousselot, advancing the capabilities of 3D bioprinting while honoring our roots at Ghent University."

Furthermore, this collaboration strengthens the expertise in gelatin and gelatin-based products in the Ghent region. The synergy between BIO INX and Rousselot enhances the region's legacy of excellence in gelatin expertise.

Tanja Vervust, Global Director of Rousselot Biomedical, highlighted the importance of streamlining the ordering process and ensuring efficient delivery of high-quality gelatins necessary for tissue engineering and biofabrication projects through online purchasing. She emphasized that Rousselot's X-Pure gelatins are functionally equivalent to GMP-grade gelatins, reducing development variability and facilitating the transition to clinical applications.



magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024